News
Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...
In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...
The team, led by Dr Phillip Jenkins, a postdoctoral fellow in clinical informatics at Oregon Health & Science University, ...
DelveInsight's,“ Fallopian Tube Cancer Pipeline Insight 2025 ” report provides comprehensive insights about 70+ Fallopian ...
A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with ...
The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.
News-Medical.Net on MSN7h
New drug-releasing system eliminates tumors in 82% of high-risk bladder cancer patients
A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback